Randomized, Double Blind,Placebo-Controlled, Multicenter Study Evaluating the Safety and Pharmacokinetics of Different Dosing Regimens of Favipiravir in Healthy Adult Subjects and Adult Subjects With Uncomplicated Influenza

Trial Profile

Randomized, Double Blind,Placebo-Controlled, Multicenter Study Evaluating the Safety and Pharmacokinetics of Different Dosing Regimens of Favipiravir in Healthy Adult Subjects and Adult Subjects With Uncomplicated Influenza

Completed
Phase of Trial: Phase I/II

Latest Information Update: 24 Oct 2015

At a glance

  • Drugs Favipiravir (Primary)
  • Indications Influenza virus infections
  • Focus Pharmacokinetics
  • Acronyms FAVOR
  • Sponsors FUJIFILM Pharma; MDVI
  • Most Recent Events

    • 01 Feb 2013 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
    • 25 Jan 2013 Planned number of patients changed from 450 to 550 as reported by ClinicalTrials.gov.
    • 22 Jan 2013 Planned number of patients changed from 228 to 450 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top